Table S5. Prognostic effect of the copy number of genomic regions. Multivariate results obtained via penalized regression.
| Chr | Region ID | CNA frequency | Disease-free survival | Overall survival | Lung-cancer specific survival | Mb | Genes | cytoBands | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Losses | Gains | HR for loss* (95% CI) | HR for gain** (95% CI) | P | HR for loss* (95% CI) | HR for gain** (95% CI) | P | HR for loss* (95% CI) | HR for gain** (95% CI) | P | ||||||||
| 1 | 3 | 9.8% | 1.6% | 0.92 (0.83–1.0) | 1.1 (0.98–1.2) | 0.129 | 6.0E+1 | EPS15, FGR, JUN, LCK, PAX7, STIL, TAL1, NBL1, EPHB2, MUTYH, NBL1, ARNT | p36.21–p31.1 | |||||||||
| 1 | 14 | 15.6% | 25.9% | 1.0 (0.92–1.1) | 0.99 (0.90–1.1) | 0.837 | 2.0E−1 | q21.2 | ||||||||||
| 3 | 71 | 2.3% | 42.6% | 1.0 (0.90–1.1) | 0.99 (0.88–1.1) | 0.919 | 3.0E−2 | q26.1 | ||||||||||
| 6 | 122 | 1.5% | 40.3% | 0.97 (0.87–1.1) | 1.0 (0.93–1.1) | 0.554 | 4.0E−3 | p24.2 | ||||||||||
| 7 | 142 | 0.7% | 17.3% | 0.97 (0.87–1.1) | 1.0 (0.93–1.1) | 0.531 | 8.0E+0 | p12.3–p11.2 | ||||||||||
| 8 | 166 | 23.5% | 7.4% | 0.98 (0.89–1.1) | 1.0 (0.91–1.1) | 0.771 | 1.0E+0 | p12 | ||||||||||
| 8 | 185 | 7.3% | 17.4% | 1.0 (0.94–1.1) | 0.96 (0.87–1.1) | 0.460 | 4.0E+0 | p11.1–q11.1 | ||||||||||
| 9 | 211 | 34.8% | 3.4% | 1.0 (0.91–1.2) | 0.98 (0.86–1.1) | 0.686 | 1.1 (0.92–1.2) | 0.94 (0.81–1.1) | 0.427 | 3.0E−1 | p21.3 | |||||||
| 9 | 214 | 40.2% | 3.0% | 1.0 (0.88–1.1) | 1.0 (0.88–1.1) | 0.984 | 1.0 (0.89–1.2) | 0.98 (0.85–1.1) | 0.724 | 3.0E−1 | CDKN2A, CDKN2B | p21.3 | ||||||
| 9 | 217 | 35.0% | 3.9% | 1.0 (0.90–1.2) | 0.98 (0.85–1.1) | 0.717 | 9.0E−3 | p21.3 | ||||||||||
| 12 | 270 | 3.9% | 16.4% | 0.98 (0.88–1.1) | 1.0 (0.92–1.1) | 0.705 | 9.0E+0 | FGF6, ING4 | p13.33–31 | |||||||||
| 14 | 312 | 8.5% | 8.9% | 1.0 (0.92–1.1) | 0.99 (0.90–1.1) | 0.844 | 1.0E−1 | q23.1 | ||||||||||
| 18 | 368 | 12.1% | 6.6% | 1.1 (0.95–1.2) | 0.95 (0.86–1.1) | 0.321 | 1.0E−3 | q12.1 | ||||||||||
| 19 | 378 | 9.2% | 0.3% | 1.1 (0.92–1.2) | 0.95 (0.84–1.1) | 0.443 | 8.0E+0 | MLLT1, SH3GL1, TCF3, VAV1 | p13.3–2 | |||||||||
| 19 | 379 | 10.3% | 0.9% | 1.0 (0.90–1.1) | 0.99 (0.87–1.1) | 0.821 | 3.0E−3 | p13.2 | ||||||||||
| 19 | 383 | 8.0% | 2.5% | 1.0 (0.91–1.1) | 0.99 (0.88–1.1) | 0.802 | 4.0E+0 | p12–p11 | ||||||||||
| 20 | 410 | 1.1% | 20.8% | 1.0 (0.9–1.1) | 0.99 (0.89–1.1) | 0.895 | 2.0E+0 | HCK | q11.21–22 | |||||||||
Results from a model adjuster by treatment arm, patient age, sex, performance status (PS), histology, T, and N stage. *, hazard ratio for a 2-fold lower copy number; **, hazard ratio for a 2-fold higher copy number.